Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Company

Acne

Pharmaceutical intelligence for Acne with 3 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals
3
Catalysts
0
Assets
3

Recent signals(3)

RegulatoryJuly 25, 2026

FDA Accepts Supplement Application for Acanya by Bausch

The FDA has accepted a supplemental application for Acanya, a topical acne treatment containing benzoyl peroxide and clindamycin phosphate.

RegulatoryJuly 20, 2026

FDA Approves Differin Epiduo Acne Gel for Acne Treatment

The FDA has approved Differin Epiduo Acne Gel, which contains adapalene and benzoyl peroxide.

StrategyJuly 9, 2026

FDA Grants Approval for Adapalene ANDA219565 by UNIQUE

The FDA has granted approval for ANDA219565, a generic formulation of Adapalene submitted by UNIQUE.

Upcoming catalysts

No catalysts indexed for this entity yet.

Regulatory activity(2)

RegulatoryJuly 25, 2026

FDA Accepts Supplement Application for Acanya by Bausch

The FDA has accepted a supplemental application for Acanya, a topical acne treatment containing benzoyl peroxide and clindamycin phosphate.

RegulatoryJuly 20, 2026

FDA Approves Differin Epiduo Acne Gel for Acne Treatment

The FDA has approved Differin Epiduo Acne Gel, which contains adapalene and benzoyl peroxide.

Clinical activity

No signals indexed for this entity yet.

Competitive activity

No signals indexed for this entity yet.

Assets

Bausch →
Galderma →
UNIQUE →

Therapeutic areas

Acne →
Dermatology →

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.